정상백서에서 성장호르몬투여가 갑상선기능에 미치는 영향

Abstract

[한글]

전공학적으로 성장호르몬합성이 가능하여 양적제한이 없어짐에 따라 성장호르몬결핍증뿐만 아니라 연골무형성증, 터너증후군등 성장호르몬결핍증이외에서도 성장호르몬계제를 많이 사용하게 되었다. 그러나 성장호르몬을 투여하였을때 갑상선기능저하증이 초래된다는 보고들이 있었다. 이에 본연구는 실험동물상 성장호르몬을 투여시 갑상선기능상태에 미치는 영향을 규명할려고한다. 실험동물로는 숫컷흰쥐 60마리를 사용하였으며 성장호르몬투여군(50마리)은 체중 kilogram당 0.5 U를 매일 일회씩 복강내 투여하었으며 투여직전, 투여후 5일, 10일, 15일 및 투여중단후 15일에 각각 10마리씩 Glucometer로 혈당을 측정하였으며 복부대동맥천자로 혈액을 채취하여 T4, T3, reverse T3, somatostatin을 측정하었다. 또한 주기적으로 체중 및 꼬리길이를 측정하여 다음과 같은 걸과를 얻었다.

1.투여기간에 따라 실험동물의 체중 및 꼬리길이의 변화는 성장호르몬투여군 및 대조군사이에 차이는 없었다.

2.성장호르몬투여군중 투여후 10일, 15일의 혈당치 는 대조군에 비해 통계적으로 유의하계 증가하였다.

3.성장호르몬투여기간에 따라 T4, T3, reverse T3, somatostatin농도는 대조군과 성장호르몬투여군 사이에 유의한 차이가 없었다.

이상의 결과로 보아 정상백서에서 성장홀몬투여자체가 갑상선기능상태에 영향을 미치지 앉는다고 생각된다.

[영문]

With the increased availability of human GH synthesized by the techniques of recombinant DNA, growth hormone(GH) has been widely used clinically in promoting growth in some non-GH deficient short children as well as in GH-deficient children.

Evidence suggested that such administration of human growth hormone in GH - deficient and non GH deficient short children may produce alterations in thyroid function and clinical hypothyroidism to produce growth slowdown.

Therefore, this study was designed to evaluate the effect of growth hormone administration on the thyroid function status informal rats.

Sixty male Sprague-Dawley rats (150 gm average body wt) were used for this study and 10 animals were served as a control and 50 animals as GH-treated group.

For the GH treated group, rats were received GH(0.5U/kg/day) intraperitoneaIly for 15 days . Rata were weighed and tail Length was Heasured before and on the 5th, 10th, 15th day of GH administration and 15th day following GH withdrawal.

Serun concentrations of thyroxine(T4), T3, and reverse T3 were determined by specific radioimmunoassay using RIA kit(Abbott Lab)and somatstation concentrations were also measured using a RIA kit (INCSTAR Lab).

Blood glucose levels were determined by glucometer.

The results obtained were as follows :

1.There were no significant differences in changes of weight and tail length between the control and GH treated groups.

2.Blood sugar levels of the control group were 56.1± 17.5 mg%, but blood sugar levels were increased to 71.1±20.3mg%, 87.9±34.9mg%, 123.8±25.0mg% on 5th, 10th and 15th day of GH treatment respectively.

Levels of blood sugar were decreased to 69.8±16.O mg% on the 15th day of withdrawal.

3.No significant difference was observed in serum concentration of T4, T3, reverse T3 and somatostatin between control and GH-treated groups.

It is, therefore, concluded that the administration of GH dries not have any influence on the thyroid function statue.